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A B S T R A C T
Alzheimer’s disease (AD) is an age-related devastating neurodegenerative disorder, which severely
impacts on the global economic development and healthcare system. Though AD has been studied for
more than 100 years since 1906, the exact cause(s) and pathogenic mechanism(s) remain to be clariﬁed.
Also, the efﬁcient disease-modifying treatment and ideal diagnostic method for AD are unavailable.
Perturbed cerebral glucose metabolism, an invariant pathophysiological feature of AD, may be a
critical contributor to the pathogenesis of this disease. In this review, we ﬁrstly discussed the features of
cerebral glucose metabolism in physiological and pathological conditions. Then, we further reviewed the
contribution of glucose transportation abnormality and intracellular glucose catabolism dysfunction in
AD pathophysiology, and proposed a hypothesis that multiple pathogenic cascades induced by impaired
cerebral glucose metabolism could result in neuronal degeneration and consequently cognitive deﬁcits
in AD patients. Among these pathogenic processes, altered functional status of thiamine metabolism and
brain insulin resistance are highly emphasized and characterized as major pathogenic mechanisms.
Finally, considering the fact that AD patients exhibit cerebral glucose hypometabolism possibly due to
impairments of insulin signaling and altered thiamine metabolism, we also discuss some potential
possibilities to uncover diagnostic biomarkers for AD from abnormal glucose metabolism and to develop
drugs targeting at repairing insulin signaling impairment and correcting thiamine metabolism
abnormality. We conclude that glucose metabolism abnormality plays a critical role in AD
pathophysiological alterations through the induction of multiple pathogenic factors such as oxidative
stress, mitochondrial dysfunction, and so forth. To clarify the causes, pathogeneses and consequences of
cerebral hypometabolism in AD will help break the bottleneck of current AD study in ﬁnding ideal
diagnostic biomarker and disease-modifying therapy.
 2013 Elsevier Ltd. All rights reserved.
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Alzheimer’s disease (AD) is an age-related and progressive
neurodegenerative disorder, characterized clinically by progres-
sive cognitive impairment and pathologically by senile plaques
and neuroﬁbrillary tangles (NFTs). It has been more than 100 years
since AD was described by German psychiatrist and neuropathol-
ogist Alois Alzheimer in 1906 (Berchtold and Cotman, 1998; Zilka
and Novak, 2006). Currently, it becomes the most common type of
dementia in the world. It is estimated to have more than 5.4 million
AD patients in America (Alzheimer’s Association, 2012), more than
6 million patients in China, and 35.6 million patients worldwide.
Alzheimer’s Disease International has predicted that people living
with AD and other dementias worldwide will increase to 67.5
million by 2030 and 115.4 million by 2050 (Alzheimer’s Disease
International, 2010). Moreover, AD also exhibited a growing
impact on global economic and social development. In USA, the
costs for dementia patients will rise from $200 billion in 2012 to a
projected $1.1 trillion (in today’s dollars) by 2050 unless
something is done (Alzheimer’s Association, 2012). The total
worldwide societal cost for dementia is estimated to be $604
billion in 2010, which is 1% of global gross domestic product (GDP),
and is predicted to increase 85% of the costs in 2030 based on
increase in the estimated number of people with dementia alone
(Alzheimer’s Disease International, 2010). However, ideal diag-
nostic biomarkers and efﬁcient disease-modifying therapies for AD
are still unavailable. Thus, developing easy-to-perform and low-
cost diagnostic approaches and the disease-modifying therapies
for AD has become a pressing issue in today’s society.
There have been a huge number of studies on AD pathogeneses,
including b-amyloid (Ab) hypothesis (Hardy and Selkoe, 2002;
Hardy and Higgins, 1992; Selkoe, 1991) and tau hyperpho-
sphorylation hypothesis (Grundke-Iqbal et al., 1986; Ihara et al.,
1986; Patrick et al., 1999). However, the precise etiologies and
pathogeneses of AD still remain to be clariﬁed, especially the
molecular pathways by which the various pathological alterations
selectively impair the cognitive domains related to learning and
memory. Although Ab hypothesis is evidenced by numerous
experimental and clinical studies, Ab vaccines that are signiﬁcant-
ly capable of reducing Ab plaques were unable to prevent disease
progression (Holmes et al., 2008). Unfortunately, to date, almost all
the clinical trials targeting at eliminating Ab deposit have done
little to improve cognitive function (Gravitz, 2011; Holmes et al.,
2008). Furthermore, effective therapy based on tau pathology is
lack (Gozes, 2010; Medina, 2011; Pritchard et al., 2011). Thisfrustrating situation has promoted us to reconsider current study
strategies for AD diagnosis and therapy. In order to develop ideal
diagnostic biomarker tests and efﬁcient disease-modifying thera-
pies for AD, greater emphasis should be paid on the initial events of
the disease.
Accumulated evidence indicates that AD is an age-related
metabolic neurodegenerative disease. The impairment in cerebral
glucose metabolism is an invariant pathophysiological feature in
AD and its occurrence precedes cognitive dysfunction and
pathological alterations even for decades (Cunnane et al., 2011;
Jack et al., 2010; Reiman et al., 1996; Small et al., 1995). Thus,
clariﬁcation of the etiological factor(s) and consequences associ-
ated with abnormal cerebral glucose metabolism will likely
provide valuable clues for treatment strategies as well as ideal
diagnostic approaches in AD. This review will discuss the
characteristic and central role of dysfunctional cerebral glucose
metabolism in AD pathogeneses.
2. Feature of cerebral glucose metabolism
2.1. Feature of cerebral glucose metabolism
The brain is an organ with the most abundant energy
metabolism in human body. On average, the adult brain accounts
for only 2% of total body weight. However, it receives about 15% of
the cardiac output and utilizes approximately 20% of total body
oxygen consumption and 25% of total body glucose in the resting
awake state (McKenna et al., 2006; Sokoloff, 1999). The fact that
the respiratory quotient of brain is nearly 1 in the physiological
state indicates carbohydrates as the predominant substrate for
oxidative metabolism of the brain (Sokoloff, 1999). Now, it is
unanimously recognized that glucose is an essential and predomi-
nant energy substrate for the adult brain under physiological
condition (Bouzier-Sore et al., 2006). Even though other alternative
substrates, like ketone bodies, glycogen and amino acids may also
be used under certain circumstances, such as during the infant
developmental period and extended fasting status in the adults,
glucose is still the dominant energy substrate for the brain in most
conditions. In addition, the limited pool size and compartmenta-
tion of these alternative substrates also restrict their capacity to
satisfy cerebral energy requirements (Henderson et al., 2009).
However, raising plasma ketones through dietary supplement
under a mild and safe level of ketonemia has been demonstrated to
enhance the proportional contribution of ketones to the brain’s
energy supply (Cunnane et al., 2011). Thus, ketones may be an
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lism in AD.
Cerebral glucose metabolism includes two main processes:
glucose transportation and intracellular oxidative catabolism.
Normal physiological glucose transportation signiﬁcantly depends
on the function of astrocytes participating in the composition of
blood brain barrier (BBB) (Molofsky et al., 2012) and various
glucose transporters distributed in the brain (Duelli and
Kuschinsky, 2001). Astrocytes play a vital role in adjusting glucose
transportation and maintaining brain energy homeostasis, which
readily take in glucose from blood through endothelial cells and
convey energy metabolic substrates between blood and neurons
(Erol, 2008; Simpson et al., 2007). Astrocytes also contain highly
amounts of glycogen granules, and more granules accumulate in
the region with more dense synapses (Phelps, 1972). It has been
demonstrated that glycogen could be used to provide lactate for
neuronal metabolism during hypoglycemia (Brown and Ransom,
2007; Pellerin et al., 2007), which may suggest astrocytes play
critical roles in both normal glucose supply and hypoglycemic
conditions. Different types of glucose transporters (GLUTs) also
take part in the transportation of glucose from blood into neurons
(Duelli and Kuschinsky, 2001). Among them, GLUT-1 and -3 are
considered to play essential roles in the modulation of brain
glucose transportation (Duelli and Kuschinsky, 2001; Simpson
et al., 1994) and in the pathogenesis of AD (Liu et al., 2008).
Intracellular oxidative catabolism is composed of complicated
pathways including glycolysis and pentose phosphate pathway
(PPP) in cytoplasma, and Krebs cycle and oxidative phosphoryla-
tion in mitochondria (Kuzuya, 1990). Glycolysis and Krebs cycle
provide reducing equivalents for oxidative phosphorylation and
ﬁnally produce ATP from ADP through oxidative respiratory chain
in mitochondria (Kuzuya, 1990), while PPP mainly plays an
important role in ﬁghting oxidative stress and synthesizing genetic
substrates of the brain (Palmer, 1999; Russell et al., 1999). Either
the abnormality of glucose transportation or intracellular oxida-
tive catabolism dysfunction affects cerebral glucose metabolism,
which likely contributes to the metabolic abnormalities in AD.
Actually, glucose transportation abnormalities due to insulin
resistance and intracellular metabolic alterations due to mito-
chondrial dysfunction have both been well demonstrated to occur
in AD patients.
2.2. Glucose metabolism dysfunction increases the risk of cognitive
impaired in the elderly
Notably, an improved understanding of physiological and
pathological regulation of glucose homeostasis is impacting on
our conception on chronic metabolic disorders of the brain
including AD. The brain’s high energy consumption dominantly
deriving from glucose metabolism makes it vulnerable to impaired
energy metabolism. In fact, both defects in hyperglycemia and
hypoglycemia homeostasis heavily affect human brain health,
especially cognitive function. The related observations have been
documented by a huge amount of clinical and experimental studies
(Biessels et al., 2006; Craft, 2005; Euser et al., 2010; Mu¨nch et al.,
1998). Substantial evidence has also shown that in aging subjects,
performance deﬁcits on a series of cognitive tasks during training
are due to insufﬁcient cerebral glucose supply. Increasing glucose
availability in selective brain areas can positively modulate
subjects’ performance in cognitive task, especially in aged animals.
Microinjection of glucose into the medial septum, hippocampus,
striatum and amygdala can enhance memory processing (Gold,
2005; McNay and Gold, 1998; Schroeder and Packard, 2003). These
ﬁndings indicate that an aging individual is at a greater risk for
exposure to glucose deprivation, especially during highly pro-
longed cognitive task or training. Now, there are a few studies toevaluate brain’s susceptibility to varying levels of low glucose in
aged, type 2 diabetes mellitus (T2DM) and AD subjects, particularly
to conﬁrm whether aged brain tissue will bear irreversible damage
at shorter intervals compared to young brain tissue (Foster et al.,
2008; Roberts and Chih, 1995). Our focus on the impairment of
hypoglycemia, especially recurrent hypoglycemic episodes, on
cognition is based on the evidence that a history of severe
hypoglycemic episodes was associated with a greater risk of
dementia among older patients with T2DM (Niswender, 2011;
Whitmer et al., 2009). Analyzing the mechanism of physiological
and pathological glucose metabolism in central nervous system
(CNS) may help to establishing long-term preventative strategies,
which thus could be used to improve metabolic buffering in the
CNS related disorders including diabetes and AD (Shetty et al.,
2011).
3. Cerebral glucose hypometabolism as an invariant biomarker
in Alzheimer’s disease
The advances in neuroimaging technology have allowed us to
investigate the relationship in detail between brain energy
metabolism and AD onset and progression. Positron emission
tomography (PET) using the tracers such as 18F-ﬂuorodeoxyglu-
cose (FDG) and 11C-Pittsbergh compound (PiB) has become the
most common and efﬁcient in vivo approach in measuring brain
energy metabolism (de Leon et al., 1983; Minoshima et al., 1997;
Small et al., 1995), amyloid-related pathology (Jack et al., 2008;
Klunk et al., 2004; Mathis et al., 2003), and the function of certain
neural circuits (Kuhl et al., 1996; Nikolaus et al., 2009; Scheltens
and Korf, 2000). In vivo 1H-nuclear magnetic resonance (MR)
spectroscopy may also be used to measure brain metabolism in
humans but is rarely available in AD (Pan et al., 2001; Shulman
et al., 2004). FDG is the suitable tracer for glucose metabolism in
the brain with the advantage that it simulates both glucose
transport and subsequent phosphorylation in glycolysis (Phelps
et al., 1979). Besides, FDG is transported into brain at nearly the
same rate as glucose. Furthermore, FDG also can be phosphorylat-
ed by hexokinase in the ﬁrst step of glycolysis. However, it cannot
be further catalyzed to fructose-6-phosphate by glucose-phos-
phate-isomerase. Hence, FDG is accumulated in the neurons as the
form of FDG-6-phosphate but without further metabolism to
produce CO2 and H2O (Cunnane et al., 2011). In AD PET studies, a
reference brain region is used to minimize inter-individual
variability in both absolute and relative measures of brain glucose
uptake, which is usually the cerebellum because of its low
involvement in AD pathology (Cunnane et al., 2011; Mosconi,
2005).
FDG-PET studies in AD have demonstrated consistent and
progressive cerebral glucose metabolism reductions, of which the
extent and topography correlate with symptom severity (Mosconi,
2005). Compared with age-matched controls, AD individuals show
regional glucose metabolism impairment in parieto-temporal lobe,
posterior cingulate cortex and the frontal areas during disease
progression (Minoshima et al., 1997; Friedland et al., 1983;). In
contrast, the primary motor and visual cortex, cerebellum,
thalamic and basal ganglia nuclei are less severely affected
(Mosconi, 2005). Previous study has shown that hypometabolism
in AD ﬁrstly arises from memory-related brain regions, like
hippocampus and entorhinal cortex, then to parietal, temporal and
posterior cingulate cortex (Mosconi, 2005). It may indicate that the
speciﬁc disease progression process occurs in AD patients.
Moreover, the reduction of local cerebral metabolic rate of glucose
estimated by FDG-PET also reﬂects the regional distribution of
reduced synaptic activity and density in AD (Pappata et al., 2008;
Rinne et al., 2003), which suggests that selectively regional
hypometabolism correlates with speciﬁc cognition impairment in
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to cerebral glucose metabolism has not been exactly identiﬁed, it
does not preclude altered cerebral glucose metabolism determined
by FDG-PET to be an effective biomarker for identifying the
presence of cognitive dysfunction-associated progressive neuro-
degeneration (95% sensitivity and 79% speciﬁcity) and yielding
higher diagnostic accuracy (89%) than clinical measures (77%)
(Silverman et al., 2001). In addition, the studies also provide
deﬁnitive evidence that FDG-PET has the capacity of high
speciﬁcity in differentiating AD from other types of dementia
(Albin et al., 1996; Silverman et al., 2001). Individuals with non-AD
type dementia manifest different patterns of FDG-PET scan from
those seen in AD patients (Silverman et al., 2003). Regional
reduction of glucose metabolism in primary occipital cortex can
efﬁciently discriminate dementia with Lewy bodies from AD (Albin
et al., 1996; Hoffman et al., 2000).
Apolipoprotein E (APOE) e4 allele is a risk factor for sporadic AD.
The subjects with two copies of APOE e4 allele have an especially
high risk of AD. In late middle age, the cognitively normal subjects
with homozygous APOE e4 signiﬁcantly showed reduced rates of
glucose metabolism in the same posterior cingulate, parietal,
temporal, and prefrontal regions as those are probably to develop
AD (Reiman et al., 1996; Small et al., 1995). Small et al. (1995)
found that in the 20 non-demented subjects carrying with APOE e4
alleles, their memory performance did not show signiﬁcant decline
during following period, but cortical cerebral metabolic rate
(CMRglu) signiﬁcantly decreased. Mosconi and his colleagues
found that the elderly subjects with homozygous APOE e4 allele
who manifest normal cognitive function can be predicted to
convert to AD by evaluating their cerebral glucose metabolism
using FDG-PET (Mosconi, 2005; Mosconi et al., 2004). Furthermore,
researchers have also observed that the cerebral glucose metabolic
reduction occurred on individuals with high risk of developing AD
before their clinical symptoms appear for several years or even
decades. For example, presenilin-1 (PS1) gene mutant carriers
from families with early onset familial AD exhibited signiﬁcant
reduced cerebral glucose metabolism with an average of 13 years
prior to the estimated age at the disease onset (Mosconi et al.,
2008a,b, 2006). These data indicate that the combination of genetic
risk with CMRglu decline would be beneﬁcial for AD prediction and
diagnosis.
As we described above, before the appearance of clinical
manifestations in AD, some functional changes can be detected,
like the hypometabolism in medial temporal lobe (Mosconi et al.,
2008a, 2006). However, the insidious onset and progressive
impairment of memory and other cognitive functions of AD make
it difﬁcult to distinguish from normal healthy aging (McKhann
et al., 1984). Thus, ﬁnding an early asymptomatic event to mark
those people who are cognitively normal seems to be important for
AD prevention and early-intervention. Clinical and research
interest has now focused on mild cognitive impairment (MCI) as
a prodromal AD stage (DeCarli, 2003; Hatashita and Yamasaki,
2010; Petersen et al., 2001; Ringman et al., 2009). MCI is proposed
as a transitional stage from healthy aging to dementia, during
which individuals have the ability to perform regular activities of
daily living but suffer isolated memory damage without or with
other domain(s) of cognitive dysfunction which is often normal in
healthy aging (DeCarli, 2003; Hatashita and Yamasaki, 2010;
Petersen et al., 2001; Ringman et al., 2009). Several studies have
demonstrated that MCI patients are at a higher risk to progress to
AD, with an estimated conversion rate of 10–15% per year
(Petersen et al., 2001). Magnetic resonance imaging ﬁndings have
also provided strong evidence that in MCI, AD-associated volume
losses could be repeatedly detected in the hippocampus, the
entorhinal cortex and parahippocampal gyrus (Hatashita and
Yamasaki, 2010; Henneman et al., 2009; Raji et al., 2009).Considering the fact that metabolism function alterations antedate
structural change in AD brain, PET imaging may provide earlier
diagnosis of this disease. With the combination of MRI, FDG-PET
studies have shown that medial temporal lobe hypometabolism is
a speciﬁc and sensitive marker for the identiﬁcation of MCI
(Mosconi, 2005).
Amnestic MCI is the most common form of MCI, with an
incidence of 1–3% in the general community and a higher risk of
developing AD (Petersen et al., 2001). The characteristic of the
amnestic MCI symptoms is objective memory impairment, deﬁned
as scores <1.5 SD below the age-matched control mean on at least
one of two delayed recall tests without other signiﬁcant deﬁcits on
detailed neuropsychological examination (Petersen et al., 2001).
Compared with amnestic MCI, other types of MCI may progress to
non-AD dementia, like frontotemporal dementia, dementia with
Lewy bodies, vascular dementia, primary progressive aphasia and
Parkinson’s disease, in which isolated memory damage does not
exist (Mosconi, 2005).
There is an apparent decrease of glucose metabolism in
hippocampal structures on FDG-PET scans in MCI (Mosconi
et al., 2005), which is particularly prominent in amnestic MCI
(Jauhiainen et al., 2008). According to previous evidence, the
topographical progression of hypometabolism in MCI brain
possibly arises from memory related regions, like hippocampus,
entorhinal cortex, then to other higher cognition-associated
neocortical regions like parietal, temporal, and ﬁnally frontal
cortex (Jauhiainen et al., 2008; Mosconi, 2005), which may reﬂect
different susceptibilities of brain regions to hypometabolism in
MCI or AD brain.
In a European multicenter study in 1999, 52 patients with
severe memory deﬁcits and Mini-Mental State Examination
(MMSE) score of 24 points or greater had been followed more
than an average of 2 years (Herholz et al., 1999). The investigators
found that impairment of temporoparietal cortex (angular gyrus
and vicinity) predicted progression of cognitive impairments by 3
MMSE points or more, with 65% sensitivity and 86% speciﬁcity.
These initial observations were followed by several studies
indicating a high predictive power of FDG-PET, with a sensitivity
of 70–93% and speciﬁcity of 47–89% for prediction of rapid
progression to dementia (Herholz, 2010; Li et al., 2008). Posterior
cingulate hypometabolism was a brain area to be recognized as an
early sign of progression in a small study of eight patients with
severe memory deﬁcits (Berent et al., 1999; Minoshima et al.,
1997; Mosconi et al., 2009). Combining with the results above,
glucose hypometabolism of temporoparietal and posterior cingu-
late association cortex can serve as a reliable biomarker for the
diagnosis of prodromal AD in MCI patients (Herholz, 2010). In a
recent analysis of longitudinal AD Neuroimaging Initiative (ADNI)
study data, Landau et al. (2010) proposed FDG-PET as a predictor in
MCI for conversion to AD combining with memory testing. As MCI
is a prodromal AD stage with a progression tendency to AD,
establishing reasonable FDG-PET imaging criteria for MCI identiﬁ-
cation is very important for the initial prediction and diagnosis of
AD.
However, it is still controversial whether the regional CMRGlu
(rCMRGlu) measured by FDG-PET exists signiﬁcant difference
between MCI and normal control. The study has showed that
cerebral glucose hypometabolism may be related to brain grey
matter atrophy and is much less pronounced after correction of
cerebrospinal ﬂuid (CSF) partial volume effects (Che´telat et al.,
2008). Devanand et al. (2010) found that rCMRGlu was decreased
in precuneus and parietal cortex in AD as compared with normal
control and MCI, but without differences between MCI and normal
control. The ratio of regional cerebral blood ﬂow (rCBF) to rCMRGlu
was found to have a similar behavior in all brain regions for young
and old subjects as shown by a correlation coefﬁcient of 88%, which
Fig. 1. The physiological process of glucose metabolism. Glucose is transported into
cells through GLUTs, and further oxidized by different enzymes. Intracellular
glucose metabolism involves four pathways: Krebs cycle and oxidative
phosphorylation that occur in mitochondria, and pentose phosphate pathway
and glycolysis that take place in cytoplasm. TPP is the co-enzyme of TK, PDHC, and
KGDHC, which are all rate-limiting of enzymes in glucose metabolism. The most
important factor to regulate glucose transport is insulin and its receptor, which is
marked by dotted line.
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of aging rather than a speciﬁc abnormal condition (Berti et al.,
2010). A study in a small sample of people suggests that the
diagnostic performance of rCMRGlu reduction in parietal and
posterior cingulate cortex may be superior to those of 11C-PiB in
distinguishing MCI from normal control (Devanand et al., 2010;
Driscoll et al., 2011). Berti et al. (2010) reported that MCI patients
were identiﬁed by PiB-PET with 75% accuracy from controls.
However, only 54% of the PiB-positive MCI patients also showed
FDG reductions, reﬂecting a dissociation between ﬁbrillar amyloid
load and rCMRglu reductions, which indicates the hypometabo-
lism of selective brain regions and Ab deposition are induced by
relatively independent pathways. Further researches need to be
performed to conﬁrm the sensitivity and speciﬁcity of cerebral
glucose hypometabolism for MCI diagnosis, as well as the match-
association of hypometabolism and Ab plaques in MCI diagnosis.
In summary, glucose hypometabolism in the selective cortical
regions is an invariant feature and a pre-clinical event both in
familial and sporadic AD. The clariﬁcation of the mechanism in
cerebral glucose hypometabolism will help not only to understand
AD pathogenesis but also to ﬁnd new diagnostic and therapeutic
targets for AD.
4. Abnormal biochemical processes of glucose metabolism in
Alzheimer’s disease
As glucose metabolism is a multi-step process regulated by a lot
of extracellular and intracellular factors (Kuzuya, 1990). Cellular
glucose metabolism mainly includes two processes: glucose
transportation and intracellular glucose metabolism. The function
of insulin signaling pathway plays a key role in regulating glucose
trans-membrane transportation (Apelt et al., 1999). T2DM is a
metabolic syndrome characterized by insulin resistance, which is
also a pathophysiological feature of AD. Thus, the links between
T2DM and AD would be a window for us to understand the
pathogenic mechanism of AD. Moreover, balanced cellular glucose
transportation also depends on the normal function of astrocytes
(Duelli and Kuschinsky, 2001) and various glucose transporters
expressed in brain (Choeiri et al., 2002; Duelli and Kuschinsky,
2001). Intracellular glucose metabolism involves four pathways:
Krebs cycle and oxidative phosphorylation that occur in mito-
chondria, and PPP and glycolysis that take place in cytoplasm
(Kuzuya, 1990). Thus, the mechanisms involved in glucose
transportation abnormalities, especially insulin resistance, and
intracellular glucose metabolic disturbance possibly contribute to
cerebral glucose hypometabolism in AD. The physiological
processes of glucose metabolism are described in Fig. 1.
4.1. Disrupted glucose transport
4.1.1. Brain insulin resistance: links between type 2 diabetes mellitus
and Alzheimer’s disease
Cognitive deﬁcits have become a challenge for T2DM patients
and vice versa, most of AD patients also show abnormal fasting
glucose and insulin resistance. Some investigators even called AD
as ‘‘Type 3 diabetes mellitus’’ or ‘‘brain insulin resistance’’(de la
Monte, 2012; Talbot et al., 2012; de la Monte and Wands, 2008;
Steen et al., 2005). Based on our understanding, there are many
similarities between AD and T2DM, including epidemiology,
clinical manifestations, pathological alterations, and pathophysio-
logical mechanism.
4.1.1.1. Epidemiologic, clinical, pathological links between type 2
diabetes mellitus and Alzheimer’s disease. DM is a heterogeneous
metabolic syndrome characterized by hyperglycemia that results
from the impairment in insulin production and/or efﬁcacy. In type1 diabetes mellitus (T1DM), the autoimmune destruction of
pancreatic b cells leads to the loss of insulin production, whereas
T2DM is mainly characterized by an impaired insulin action—
insulin resistance. Globally, estimates pointed to 250 million
diabetic patients worldwide in 2010, with 90% of the patients being
involved by T2DM (Correia et al., 2012; Roriz-Filho et al., 2009).
Aging is a high risk factor of T2DM, and most of T2DM patients are
elderly people. Currently, T2DM has become a common disease
that seriously affects the life quality and span of the elderly people
due to the long-term complications but not diabetes itself. These
complications include cardiovascular disease, nephropathy, reti-
nopathy, peripheral, autonomic neuropathy, and encephalopathy
(Duarte et al., 2012; Sims-Robinson et al., 2010).
T2DM has been demonstrated to be correlated with AD. The
individuals with T2DM have a two- to three-fold increased relative
risk of AD, independent of the risk for vascular dementia (Arvanitakis
et al., 2004; Leibson et al., 1997). A neuroimaging study using MRI
showed that older patients with T2DM have a moderately increased
risk for developing hippocampal atrophy and that the severity of
lesions parallels the progression of T2DM. Moreover, T2DM has also
been demonstrated to have a high risk of developing MCI.
Furthermore, metabolic syndrome characterized by insulin resis-
tance has also been demonstrated to have increased risk of AD
(Ferreira et al., 2010; Garcia-Lara et al., 2010; Janson et al., 2004).
Conversely, AD patients exhibit signiﬁcantly increased prevalence of
T2DM and impaired fasting glucose as compared to control subjects,
which over 80% of AD patients comorbid T2DM and impaired fasting
glucose (Janson et al., 2004; Li and Holscher, 2007). Using an ex vivo
stimulation protocol with near physiological doses of insulin, Talbot
K and his colleagues identiﬁed prominent brain insulin resistance of
post-mortem AD patients even in the absence of diabetes (Talbot
et al., 2012). Thus, these results suggest that T2DM is closely
correlated with AD in their epidemiology.
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showed similar clinical symptoms and signs, including cognitive
impairment, impaired fasting glucose, chronic hyperglycemia,
hippocampal atrophy. As what we discussed above, T2DM has a
high risk of cognitive impairment, possibly due to chronic
hyperglycemia, repeated occurrences of severe hypoglycemia,
microvascular complications, and insulin resistance during the
process of disease. It indicates that T2DM has a signiﬁcant impact
in the patients’ brain function (McNay and Recknagel, 2011;
Moreira et al., 2009). In addition to above-mentioned dysfunction,
many other conditions associated with T2DM may combine to
facilitate its cognitive impairment, including stroke, hypertension,
dyslipidemia, and obesity (McNay and Recknagel, 2011; Reijmer
et al., 2010). The association between metabolic syndrome and
cognitive deﬁcit suggests that metabolic dysfunction may increase
the risk of neurodegeneration (Reijmer et al., 2010; Roriz-Filho
et al., 2009). Actually, patients with T1DM and T2DM have been
previously shown to exhibit cognitive dysfunction and brain
structure abnormalities (Correia et al., 2012; Kim and Feldman,
2012). Moreover, brain atrophy in T2DM patients is very
prominent in cortical, subcortical, and hippocampal areas (Biessels
et al., 2002; Correia et al., 2012), which has been demonstrated to
be associated with cognitive impairment. In T1DM patients,
cognitive deﬁcit appears to be mainly attributed to its short-term
complications, like acute hyperglycemia and/or hypoinsulinemia,
which lead to lower performance on cognitive function tests
(McNay and Recknagel, 2011; Roriz-Filho et al., 2009). However, in
T2DM, the decline in cognitive function seems to be more related
to elderly patients, which may be explained by insulin resistance
that prevalently occurs in these patients (Duarte et al., 2012;
McNay and Recknagel, 2011). Considering the effects T2DM on
cognitive impairment, it is no doubt that T2DM patients should
have higher risk to suffer from degenerative disease, including AD.
Ab plaques and NFTs are two pathological markers of AD brain.
Interestingly, a few of studies also showed that T2DM exhibited Ab
accumulation in similar regions from post-mortem brains (de la
Monte and Wands, 2008; Steen et al., 2005). Impaired insulin
signaling pathway increases Ab accumulation in T2DM patients
(Steen et al., 2005). Besides, in a model of T2DM produced by
intracerebral injection of streptozotocin (STZ), de la Monte et al.
found that brains with T2DM were atrophied and had evident
neurodegeneration with neuron loss, gliosis, activated glycogen
synthase kinase-3b (GSK-3b), hyperphosphorylated tau, and Ab
deposit, which are the features of AD brains (de la Monte and
Wands, 2008; Lester-Coll et al., 2006). Moreover, the deﬁciency of
insulin receptor (IR) substrate-2 has also been reported to reduce
brain growth and enhance tau phosphorylation. Hence, these
studies possibly indicate that T2DM shares some pathological
alterations with AD.
4.1.1.2. Impaired insulin signaling in type 2 diabetes mellitus and
Alzheimer’s disease. Actually, there is a huge body of evidence
supports impaired insulin signaling to be the fundamental
correlation between T2DM and AD (Bomﬁm et al., 2012; Zhao
et al., 2008a,b). Furthermore, the studies have showed that the
dysfunction of cerebral insulin signaling pathway exacerbated
neurodegeneration and synaptic loss, which are responsible for
cognitive deﬁcits (Bosco et al., 2011; de la Monte, 2012; Matsuzaki
et al., 2010; Schrijvers et al., 2010).
Insulin and its receptor are the key factors for modulating
glucose availability and energy homeostasis both for CNS and
peripheral systems. IRs are widely expressed throughout CNS
(Baskin et al., 1988; Havrankova et al., 1978; Zhao et al., 1999). The
study have reported that AD exhibits the decrease in CSF insulin
levels, the ratios of CSF insulin over plasma insulin, IR expression,
and the increase in fasting plasma insulin levels (Moloney et al.,2010). Once the dysfunction of insulin signaling pathway emerges
in brain, cerebral glucose availability and energy homeostasis will
be disturbed. Most of the energy generated in brain is used for the
transmission of synaptic signals. Intermediate metabolites of
glucose such as acetyl coenzyme A and succinyl coenzyme A are
the precursors of acetylcholine, a neurotransmitter closely linked
to cognitive function. Thus, brain energetics contributes to
neurotransmission associated with cognitive dysfunction (Kann
and Kovacs, 2007). Impaired cerebral glucose availability rapidly
causes the dysfunction of cognition-related synaptic transmission.
Based on the results from the previous studies, the reduction of
expression of insulin, insulin-like growth factor type-1 and 2 (IGF-
1 and IGF-2) as well as their receptors participates in the
pathogenesis of AD. Steen et al. (2005) has demonstrated that
the expression of insulin and IGF-1/2 receptors markedly reduce in
AD brains, which is correlated with the pathological alterations,
including increased GSK-3b activity and APP mRNA level.
Moreover, the studies have demonstrated that endogenous
deﬁciencies of genes encoding insulin, IGF-1, IGF-2 peptides and
their receptors, can occur in AD brain without T2DM. These
alterations are involved in the progression of AD according to Braak
staging (Rivera et al., 2005). In addition, the disruption of insulin
transportation may partially contribute to the decreased CSF
insulin and IGF-1 levels in AD (Bosco et al., 2011; de la Monte,
2009), which is associated with decreased BBB function induced by
continuous peripheral hyperinsulinemia (Bosco et al., 2011; Li and
Holscher, 2007). However, neurons in brain also express and
secrete the insulin (Kuwabara et al., 2011), and in AD brain, insulin
mRNA expression was 4-fold lower in the hippocampus and 2-fold
lower in the hypothalamus compared to control brains (Steen et al.,
2005). Thus, both mechanisms of transportation disruption and
local secretion dysfunction can induce the declined insulin level in
AD brain. Beyond the above-mentioned mechanisms, impaired
binding between insulin, IGF-1 and their receptors also was
observed in AD, which is associated with changes in membrane
cholesterol levels which affected the membrane dynamics upon
aging and/or APOE4 genotype (de la Monte, 2009; Li and Holscher,
2007). Chua et al. (2012) has demonstrated that impaired insulin
signaling precedes Ab accumulation, which implies the impor-
tance of reduced insulin signaling among pathogenic factors of
Alzheimer’s neurodegeneration.
Insulin/IGF-1 signaling defects predominantly involve in
phosphatidylinositide 3-kinases (PI3K)/Akt pathway through
producing harmful cascades in glucose metabolism (Liu et al.,
2011). It was recently proposed that decreased expression and
function of PI3K/Akt-mediated GLUTs in AD brain could lead to
brain glucose hypometabolism and the subsequent decline in
mitochondrial ATP production (Bosco et al., 2011). By comparing
the function of brain insulin-PI3K-Akt signaling pathway in the
frontal cortices of AD, T2DM, T2DM with AD, and control subjects,
Liu et al. (2011) found that the deﬁciency of insulin-PI3K-Akt
signaling was more signiﬁcant in subjects with both T2DM and AD.
Furthermore, their studies also showed that the levels and the
activation of the insulin-PI3K-Akt signaling components correlated
negatively with the level of tau phosphorylation and positively
with tau O-GlcNAcylation, suggesting that impaired insulin-PI3K-
Akt signaling might contribute to neurodegeneration in AD
through decreased O-GlcNAcylation and consequent tau hyper-
phosphorylation.
Recently, Bomﬁm et al. (2012) reported that Ab oligomers could
activate the tumor necrosis factor a/c-Jun N-terminal kinase
pathway, induce IR substrate-1 (IRS-1) phosphorylation at multiple
serine residues, and inhibit physiological phosphorylated IRS-1 (at
Tyr896) in cultured hippocampal neurons. Moreover, the im-
pairment of IRS-1 signaling was also observed in APP/PS1 transgenic
mice as well as in cynomolgus monkeys intraventricularly injected
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alterations were also found in human AD brains by Talbot et al.
(2012). These results showed that AD patients with T2DM may be
closely associated with IRS-1 dysregulation and IGF-1 resistance.
However, the pathophysiological alterations associated with
cerebral insulin signaling dysfunction in AD are much more
complicated than we anticipated (Arab et al., 2011). It has also been
reported that other factors involved in insulin resistance such as
mitogen-activated protein kinase (MAPK) pathway, GSK-3, insulin
degrading enzyme (IDE) and microvascular dysfunction are
responsible for AD pathophysiological alterations (Arab et al.,
2011; Carro and Torres-Aleman, 2004; Dorr et al., 2012; Farris
et al., 2003; Yan et al., 1996). MAPK pathway also has been shown
to be signiﬁcantly activated in AD patients, which is correlated
with increased neuroinﬂammation, tau hyperphosphorylation,
and Ab trafﬁcking (Bosco et al., 2011). Actually, tau hyperpho-
sphorylation is probably related to an excess activation of GSK-3b,
MAPK, and cyclin-dependent kinase 5, which are major tau kinases
responsible for tau phosphorylation (de la Monte, 2009; Moreira
et al., 2009). Moreover, the decreased phosphorylation of GSK-3a
and the increase in its activity may facilitate g-secretase activity
and APP processing, resulting in increased intracellular Ab levels
(Kim and Feldman, 2012; Moreira et al., 2009). Insulin has been
also proposed to regulate extracellular Ab degradation by
modulating IDE activity (van der Heide et al., 2006). IDE is a
zinc-metalloprotease that participates in the degradation of
several extracellular substrates, like insulin and Ab. Thus, low
IDE activity in diabetes patients may contribute to increase Ab
levels in the brain. The study demonstrated that the reduced mRNA
and protein levels as well as activity of IDE were negatively
correlated with hippocampal Ab1-42 content in severe AD patients
(Zhao et al., 2007).
To sum up, the dysfunction of insulin/IGF signaling and
associated factors is a common pathophysiological mechanism
to induce neurodegeneration in T2DM and AD. Therefore, some
investigators have proposed the term, T3DM or brain insulin
resistance, to reﬂect the dysfunction of insulin signaling pathway
in AD (de la Monte and Wands, 2008; Steen et al., 2005). Insulin-
sensitizing agents such as ligands for g-peroxisome proliferator-
actived receptor (g-PPAR) and intranasal insulin have offered a
potential therapeutic solution (Brodbeck et al., 2008; Reger et al.,
2008a,b). The study by Zhao et al. (2008a,b) showed that neuronal
insulin signal transduction was prone to be disrupted by soluble
Ab oligomers, which caused a rapid and substantial loss of
dendritic IRs through redistribution of the receptors, suggesting
that soluble Ab oligomers are responsible for insulin resistance
and synaptic dysfunction in AD brain. Some studies have proved
that insulin treatment prevents the binding of Ab oligomers with
IR and synapse loss (De Felice et al., 2009; Gasparini et al., 2001), as
well as improves cognitive dysfunction in AD.
Apart from insulin resistance, other pathophysiological
alterations in T2DM also could occur and even play signiﬁcant
roles in AD, such as elevated advanced glycation end products
(AGEs) and transformation growth factor (TGF). The term ‘‘AGEs’’
is currently used for a broad range of advanced products of the
glycation process (also called the ‘‘Maillard reaction’’) (Martina
and Gerald, 2010). The previous evidence has demonstrated that
AGEs contribute to the pathological process of T2DM as well as
AD (Gasser and Forbes, 2008; Li and Holscher, 2007; Martina and
Gerald, 2010). AGEs formation is accelerated in T2DM and
correlated with T2DM-associated vascular complications (Tan
et al., 2006). On the other hand, AGEs also play an important role
in AD pathogenesis (Martina and Gerald, 2010). Immunohisto-
chemical studies have showed AGEs present in senile plaques
(Kimura et al., 1995) as well as in NFTs (Castellani et al., 2001).
Ab, AGEs, and APOE were positively immunoreactive in most ofthe plaques in hippocampus of AD patient (Martina and Gerald,
2010; Sasaki et al., 2001). Besides, Ab-, AGEs-, and the receptor
of AGEs (RAGE)-positive granules were also found in hippocam-
pus neurons (Martina and Gerald, 2010). In cell culture studies,
the cytotoxic effect of AGEs was completely prevented by the
addition of the anti-AGE-2-speciﬁc antibody, but not by other
types of anti-AGE antibodies (Takeuchi et al., 2000), which may
indicate that only speciﬁc type of AGEs could contribute to the
pathology of AD. T2DM patients also have higher TGF-b1 levels
in plasma and kidney than normal controls (Yener et al., 2007).
Besides, hyperglycemia was demonstrated to trigger the eleva-
tions of TGF-b1 in patients with T2DM (Yener et al., 2007).
Increase of TGF-b1 also has been demonstrated in STZ-induced
T2DM rats (Shankland et al., 1994). Moreover, suppression of
TGF-b signaling reduced mesangial expansion and interstitial
ﬁbrosis in experimental T2DM nephropathy (Ziyadeh et al.,
2000), which indicates that TGF-b may participate in the
inhibition of inﬂammatory factors induced by T2DM. Corre-
spondently, TGF-b1 has been demonstrated to have an anti-
inﬂammatory effect in brain. In AD, TGF-b1 was shown to reduce
Ab accumulation and increase Ab clearance (Wyss-Coray et al.,
2001). TGF-b1 was found within senile plaques, while TGF-b2
was found in NFTs in AD brains, suggesting that TGF-b1 plays a
protective role in AD by clearing Ab plaques and TGF-b2 seems
to be a response against NFTs in neurons. Further investigation
reveals that TGF-b1 may exert its protective role in AD by
increasing B-cell lymphoma-2 (bcl-2) expression (Prehn et al.,
1994), which is a well-known apoptotic inhibitory factor and
balancing calcium dynamics in cultured neurons. Furthermore,
suppression of TGF-b1 expression leads to elevations of Ab
levels and b-secretase-cleaved soluble amyloid precursor
protein (APP) (Tesseur et al., 2006). The above-mentioned
evidence suggests that TGF plays a signiﬁcant role in both
T2DM and AD pathology.
In all, T2DM and AD show many similarities in epidemiology,
clinical manifestations, pathological alterations, and altered signal
transduction pathways. Among these common features, insulin
resistance is the most similar characteristic in T2DM and AD.
4.1.2. Abnormal glucose transporters
The abnormal transport of glucose from blood to astrocytes, and
from astrocytes to neurons is associated with many CNS diseases
(Harr et al., 1995; Kaushik Shah, 2012; Simpson et al., 1994), which
may also be related to the function of many glucose transporters
expressed in brain.GLUT1 mediates glucose transport from blood
to astrocytes and includes two isoforms based on the difference of
molecular weight: 55-kD GLUT1 expressed in endothelial cells of
brain vessels and 45-KD GLUT1 mainly expressed in astrocytes
(Duelli and Kuschinsky, 2001). GLUT3 is the mostly distributed in
neurons and has a low Michaelis-Menten constant, which
facilitates the continuous supply of glucose to the neurons even
at low interstitial glucose concentrations (Duelli and Kuschinsky,
2001). Other types of glucose transporters, like GLUT4 and GLUT5
(Apelt et al., 1999; Duelli and Kuschinsky, 2001; Kaushik Shah,
2012), also distribute in brain. GLUT4 is insulin-responsive (Apelt
et al., 1999) and only expresses in some speciﬁc type of neurons,
like hippocampus neurons (Piroli et al., 2007).
The association of cerebral glucose transport dysfunction with
AD pathology has been clinically investigated. AD patients show
decreased GLUT1 and GLUT3 expressions, especially in the
cerebral cortex (Simpson et al., 1994). The dentate gyrus of
hippocampus also exhibits decreased GLUT3 expression (Harr
et al., 1995). Signiﬁcant decline in expression levels but without
statistical changes in mRNA levels of GLUT1 in the human AD
brain suggests a post-transcriptional regulation mechanism
(Mooradian et al., 1997).
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acetylglucosamine (O-GlcNAc) transferase, which is required for
catalyzing O-GlcNAcylation of Ser/Thr protein residues (Liu et al.,
2009). Its production needs 2–5% energy provided by glucose
oxidative phosphorylation. Liu et al. (2008) reported the decreased
O-GlcNAcylation paralleled GLUT1 and GLUT3 reductions, and it is
shown to be negatively correlated between GLUT1 and GLUT3
reduction and tau phosphorylation levels. Thus, they proposed that
diminished expression of glucose transporters could induce
hypometabolism in the brain, which decrease the O-GlcNAcylation
of tau and conversely increase its phosphorylation (Liu et al., 2008).
Finally, the tau hyperphosphorylation-induced NFTs underlie the
cognitive deﬁcits of AD subjects.
The T2DM brain had a decreased level of neuronal GLUT3
expression as compared to AD brain. In addition, the decrease in O-
GlcNAcylation and increase in tau phosphorylation were also
observed, which is similar to the AD brain (Liu et al., 2009). It may
suggest that the dysfunction of glucose transportersmay be the
common feature of T2DM and AD pathology.
Based on the regulation mechanism of glucose transporter
expression (Liu et al., 2008), it is more likely that reduction of
GLUT1 and GLUT3 expression is the result of decreased energy
demand of some brain regions in AD brain, but rather presented as
an initiated force that causes brain hypometabolism in AD brain.
Hence, Liu’s study (Liu et al., 2009) can be alternatively explained
that hypometabolism results in both reduced glucose transporters
expression and decreased O-GlcNAcylation of tau. To date, no
deﬁnitive links were established between the altered glucose
transporter function and disease progression.
4.2. Intracellular glucose metabolic disturbance
By intracellular catabolism, glucose is eventually transformed
into adenosine triphosphate (ATP) and the metabolites (e.g. acetyl
coenzyme A and succinyl coenzyme A) to provide the energy for
neural activities and the substrates for biosynthesis. The processes
of intracellular glucose catabolism are mainly involved in four
pathways: Krebs cycle and oxidative phosphorylation that mainly
occur in mitochondria, and PPP and glycolysis that take place in
cytoplasm. Mitochondrial dysfunction has been widely conﬁrmed
both in clinical and experimental studies of AD (Beal, 2005; Bubber
et al., 2005; Lustbader et al., 2004; Schapira, 2012). Notably, as
three key enzymes in Krebs cycle and PPP, the activities of pyruvate
dehydrogenase complex (PDHC), a-ketoglutarate dehydrogenase
complex (KGDHCC) and transketolase have been demonstrated to
decrease in AD (Gibson et al., 1988; Mastrogiacoma et al., 1996a;
Sheu et al., 1988; Sorbi et al., 1983). Their common coenzyme,
thiamine diphosphate (TDP), also showed altered levels both in
blood and brain of AD patients (Gold et al., 1998; Mastrogiacoma
et al., 1996a). These results indicate the important roles of
mitochondrial dysfunction and impaired thiamine-dependent
processes in cerebral glucose hypometabolism of AD.
4.2.1. Altered functional status of thiamine metabolism
4.2.1.1. Decreased activities of thiamine-dependent enzymes. The
decreased activities of mitochondrial thiamine-dependent enzymes
are also the prominent manifestations in AD, which provides us an
alternative clue to explore the culprit of mitochondrial dysfunction
and cerebral glucose metabolic abnormality. The Krebs cycle and
oxidative phosphorylation of glucose metabolism mainly occurring
in mitochondria are essential for maintaining normal cerebral
function and offer 95% of brain energy fuels (Bonda et al., 2010). The
Krebs cycle and oxidative phosphorylation of glucose are signiﬁ-
cantly disrupted in AD brains possibly due to the alterations of
relevant enzymes, especially two key enzymes: PDHC and KGDHC(Gibson et al., 1988). Bubber et al. (2005) tested impairments in the
Krebs cycle enzymes of mitochondria in AD patients and found
signiﬁcantly decreased PDHC and KGDHC activities while the
activities of the other four Krebs cycle enzymes were unchanged. In
fact, many studies have veriﬁed this phenomenon that the activities
of thiamine-dependent PDHC and KGDHC signiﬁcantly decrease in
peripheral and brain tissues of AD patients (Butterworth and
Besnard, 1990; Gibson et al., 1988; Ko et al., 2001; Paoletti et al.,
1990). In addition, transketolase, another thiamine-dependent key
enzyme in non-oxidative branch of PPP is also signiﬁcantly altered
both in peripheral and cerebral tissues (Butterworth and Besnard,
1990; Gibson et al., 1988; Paoletti et al., 1990; Sheu et al., 1988). It
catalyses the conversion of D-xylulose 5-phosphate and D-ribose 5-
phosphate to D-glyceraldehyde 3-phosphate and D-sedoheptulose
7-phosphate, and needs TDP and divalent metal ions such as Mg2+ as
cofactors (Schenk et al., 1998). Transketolase-catalyzing reactions
play an important role in the exchange of glycolysis and oxidative
branch of PPP (Butterworth and Besnard, 1990). To date, several
sources of evidence have suggested transketolase was modiﬁed in
AD. Transketolase activity has been shown to decrease ﬁrst and to
recover last following thiamine repletion in animals (Giguere and
Butterworth, 1987), which may indicate that transketolase is much
more sensitive to thiamine change than other thiamine-dependent
enzymes. Reduced transketolase activity has been demonstrated in
red blood cells, ﬁbroblasts, and brain tissues from AD patients. The
study on erythrocytes from AD shows reduced transketolase
activity, which suggests structural abnormalities of transketolase
rather than thiamine deﬁciency in AD (Butterworth et al., 1993; Sheu
et al., 1988). Other data suggest abnormalities in proteinase actions
contribute to the transketolase alterations. In cultured ﬁbroblasts
from AD patients, transketolase was shown to have an unusually
high pI, which is characterized as a maker of Alzheimer’s disease
(Tombaccini et al., 1994). Further studies showed that it is attributed
to the abnormal cysteine proteinases actions (Paoletti and Mocali,
1991; Paoletti et al., 1997). Brain cortical tissues from AD patients by
biopsy also have been demonstrated to have low transketolase
activity by 52% decrease (Butterworth and Besnard, 1990). Our
previous study demonstrated that thiamine deﬁciency (TD)
impaired hippocampal neurogenesis by inducing low transketolase
activity (Zhao et al., 2008a,b, 2009). However, there is no deﬁnitive
evidence to prove transketolase abnormality correlates with AD
pathology, and the alteration of transketolase activity did not
parallel AD progression (Schenk et al., 1998). Because TDP, active
form of thiamine, is an essential coenzyme for mitochondrial PDHC
and KGDHC as well as cytosolic transketolase in catalyzing the
reactions of glucose metabolism, it suggested that altered thiamine
metabolism is involved in abnormal glucose metabolism in AD.
4.2.1.2. Thiamine and glucose metabolism. As what we mentioned
above, three thiamine-dependent enzymes (transketolase, PDHC
and KGDHC) play the important roles in glucose metabolism
(Schenk et al., 1998; Shoffner, 1997). Transketolase is the rate-
limiting enzyme of non-oxidative branch in PPP (Butterworth and
Besnard, 1990; Butterworth et al., 1993; Gibson and Blass, 2007),
which is critical in the interchange of metabolites between
glycolysis and the pentose shunt (Kauffman, 1972). PDHC is the
entry point for carbon, as the form of acetyl CoA, where carbons
were transported into the tricarboxylic acid (TCA) cycle to be
oxidized (Kuzuya, 1990; Shoffner, 1997). KGDHC is the rate-
controlling step of the TCA cycle under physiological conditions
(Butterworth and Besnard, 1990). Thus, thiamine-dependent
processes modulate essential aspects of brain glucose metabolism
that are critical to normal brain function.
Furthermore, thiamine also takes part in the regulation of
oxidative stress and carbonyl stress. Glycolysis is a crucial process
for providing some reducing equivalents for respiration chain.
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glycolysis (Gibson et al., 2012; Kuzuya, 1990), which is produced
with two units of equivalents. It has been demonstrated that the
increased level of glyceraldehyde-3-phosphate enhances carbonyl
stress and leads to the increased formation of methyglyoxal and
AGEs, which play an important role in the development of chronic
disease, including T2DM and its complications. The response of
thiamine to AGEs has been demonstrated in vivo. Thiamine seems
to play an essential role in maintaining enough cellular defenses
against the accumulation of AGEs (Shangari et al., 2007). Plasma
AGEs was shown to increase even thiamine is marginally TD
(Lonsdale, 2006; Shangari et al., 2003). In addition, increased
oxidative stress by marginal TD in a dose dependent manner has
been conﬁrmed by increased AGEs concentration in plasma and
tissues (Shangari et al., 2007).
Moreover, thiamine inhibits lipid peroxidation in liver micro-
somes, reduces free radical oxidation of oleic acid in vitro
(Lukienko et al., 2000), and elevates glutathione reductase activity
following cardiac hypoperfusion (Tolstykh and Khmelevskii Iu,
1991). In mice, TD elevates many markers of oxidative stress. These
markers are also elevated in brains from AD patients (Calingasan
and Gibson, 2000). Dietary TD and other sources of oxidative stress
increase AGEs synergistically (Shangari et al., 2005). From all these
observations, it can be easily concluded that TD not only
contributes to the dysfunction of glucose metabolic process, but
also leads to serious oxidative stress in cells, which may play
essential roles in the pathogenesis of metabolic syndrome, as well
as AD.
4.2.1.3. Increased risk of thiamine deﬁciency in elderly. Aging is a key
risk factor for AD. Also, the studies have found that the elderly is a
high-risk population suffering from TD. Under the condition of that
average daily thiamine intake was above the recommended
requirement (>0.4 mg/1000 Kcal), almost half of the elderly
population (older than or equal to 65 years) had an effect of TDP on
the transketolase activity above 14%, suggesting TD (Nichols and
Basu, 1994). The study raised questions about the reliability of
dietary intake in assessing metabolic availability of thiamine in the
elderly. A cross-sectional and 3-year longitudinal survey suggested
that lower TDP concentration in the elderly people appears to be
related more to age itself than to co-existent illnesses (Wilkinson
et al., 2000). Interestingly, the reported prevalence of biochemical
TD ranges from 8% to 31% for elderly people living at home in
United Kingdom of British and is signiﬁcantly higher than those
living in nursing homes (23–40%) and those admitted in acute
geriatric ward (48%) (O’Keeffe, 2000).
4.2.1.4. Altered functional status of thiamine metabolism. The
previous studies have reported that the activities of thiamine
diphosphatase (TDPase) and thiamine monophosphatase
(TMPase) were decreased in AD brains (Heroux et al., 1996). In
frontal and temporal cortex, TDPase activities declined by 28% and
62% in AD patients, respectively, and reduced rate for TMPase in
these two regions is 31% and 64%, respectively, in the same brain
samples (Heroux et al., 1996). The activities of TMPase and TDPase
occurred not only in pathological regions but also in normal
regions (Gibson and Blass, 2007). It is different from brain glucose
hypometabolism that happens selectively in some cerebral
regions. Paradoxically, the levels of thiamine phosphorylated
esters, TDP and thiamine monophosphate (TMP), were reported to
decline signiﬁcantly both in bloods and brains of AD patients by
most of the studies (Glasø et al., 2004). Are decreased activities of
TDPase and TMPase compensatory responses for reduced levels of
TDP and TMP or caused by other factor(s)? It is still a puzzle.
Contrasted to consistently decreased TDP levels in all AD studies,
TMP and free thiamine levels were controversially altered in ADstudies (Heroux et al., 1996). The study for autopsied brain tissues
found that the level of TDP was signiﬁcantly reduced by 18–21%
whereas the levels of free thiamine and TMP were normal in all
three cortical areas examined in the AD group as compared with
control group (Mastrogiacoma et al., 1996a). Gold (2005)
demonstrated the speciﬁcity of altered thiamine metabolism
for AD, which signiﬁcantly lower plasma thiamine level was found
in AD but not in Parkinson’s disease, another neurodegenerative
disorder characterized by movement abnormality. Whatever, all
these evidence may suggest that AD patients widely exhibit a
disruption of thiamine phosphorylation–dephosphorylation pro-
cesses.
The phosphorylated derivatives of thiamine have widely
physiological effects in glucose metabolism, protein processing,
gene expression and lipid metabolism (Gibson and Blass, 2007;
Mastrogiacoma et al., 1996b; Tylicki and Siemieniuk, 2011). It is
easy to suppose that the decreased activities of thiamine-
dependent enzymes lead to glucose hypometabolism in cognitive-
ly normal people as well as in cognitively impaired patients.
Besides, low glucose metabolism also causes oxidative stress and
increases neuron’s structural and functional impairments, includ-
ing lipid peroxiation, apoptosis, electron chain uncoupling and so
on (Gibson and Blass, 2007; Gibson et al., 2012).
It remains to be clariﬁed the cause of altered thiamine
metabolism in the elderly and AD subjects. There has been no
study yet to demonstrate whether abnormal Ab metabolism plays
a role in altered thiamine metabolism. Thiamine uptake occurs in
the human intestine via a specialized carrier-mediated mecha-
nism and its functional conversion into TDP takes place in
cytosolic compartment through the reaction catalyzed by thia-
mine pyrophosphate kinase (TPK). TDP is decomposed into TMP
by TDPase and TMP is converted into thiamine by TMPase in
cytoplasm. Thus, the balance of TPK and TDPase activities
maintains the homeostasis of functional thiamine metabolism.
Young people have a sufﬁcient thiamine absorption in the
intestine whereas the elderly manifests a declining trend
following the age increase (Baum and Iber, 1984). The absorption
of oral thiamine in older individuals was found to be poor as
compared with that in young individuals (Tallaksen et al., 1993). It
may be associated with the decreased activities of intestinal
alkaline phosphatase in the elderly subjects (Detel et al., 2008;
Rindi et al., 1995; Schaller and Holler, 1975). In addition, a case
report also showed that thiamine couldn’t be transported into the
lumen of the gastrointestinal tract under the condition of alkaline
phosphatase deﬁciency (Luong and Nguyen, 2005). However,
there was no study to demonstrate the relationship between
alkaline phosphatase and AD.
4.2.2. Mitochondrial dysfunction and oxidative stress
The feature of cerebral high energy consumption in maintaining
normal neuronal and synaptic activities requires the appropriate
mitochondrial function for ATP generation in brain. Two essential
glucose metabolic pathways occur in mitochondria: Krebs cycle
and oxidative phosphorylation. Abnormal Krebs cycle or/and
oxidative phosphorylation cause(s) not only glucose hypometa-
bolism but also multiple pathophysiological cascades such as
apoptosis, oxidative stress, and so forth.
4.2.2.1. Perturbed Krebs cycle and oxidative phosphorylation. Krebs
cycle, namely citrate acid or TCA cycle, is crucial for the production
of reducing equivalents to oxidative phosphorylation for ATP
synthesis in mitochondria. Glucose metabolism impairment can be
attributed to the dysfunction of TCA cycle if basic components for
its normal operation or key enzymes in this cycle present deﬁcit(s),
which reduce the supply of equivalents to oxidative phosphory-
lation.
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It starts with the acetyl CoA provided through the oxidative
decarboxylation of pyruvate catalyzed by PDHC (Kuzuya, 1990).
TCA cycle involves eight enzymes: citrate synthase, aconitase,
isocitrate dehydrogenase, KGDHC, succinate thiokinase, succi-
nate dehydrogenase, fumarase, and malate dehydrogenase
(Bubber et al., 2005; Gibson et al., 2012). AD-related reduced
activities of PDHC have been robustly documented by a lot of
groups (Bubber et al., 2005; Butterworth and Besnard, 1990;
Perry et al., 1980; Sorbi et al., 1983). Declined activity of KGDHC
has been reported by four independent groups and appears to be
highly associated with the occurrence of clinical dementia
(Gibson et al., 2000). The decreased activities of these enzymes
actually do not represent a wide mitochondrial dysfunction,
considering that the activities of other mitochondrial enzymes,
like glutamate dehydrogenase or fumarase, remain normal in AD
brain. Bubber et al. (2005) found signiﬁcantly decreased activities
in PDHC (41%), isocitrate dehydrogenase (27%), KGDHC
(57%), and increased activities of succinate dehydrogenase
and malate dehydrogenase. The activities of the other four TCA
cycle enzymes were unchanged.
PDHC regulates TCA cycle by providing acetyl CoA through
pyruvate metabolism; Reduced activities of PDHC (Perry et al.,
1980; Sorbi et al., 1983) and KGDHC (Butterworth and Besnard,
1990; Gibson et al., 1988) are present both in normal and
pathological areas of AD brain. Quantity analysis of PDHC by
immunoblot in AD brain suggested that the reduced protein levels
of this enzyme complex are consistent with the decreased
enzymatic activities. In contrast to PDHC, the studies have
suggested that the reduction of KGDHC activity is not involved
in the expression level of enzyme protein (Mastrogiacoma et al.,
1996b; Sheu et al., 1985). Although an inherited genetic defect in a
KGDHC subunit was reported the association with AD (Sheu et al.,
1994), no pathogenic mutations have been identiﬁed. It has been
known that both PDHC and KGDHC present low activities in AD
brain, which may lead to glucose hypometabolism, oxidative
stress, as well as mitochondrial dysfunction of neurons.
As the ﬁnal step of bioenergetics, oxidative phosphorylation
plays an essential role in the production of ATP from ADP, which
drives the neurons to exert variety of physiological functions,
including neurotransmission, ion balance and so on. Cerebral
glucose hypometabolism induced by dysfunction of oxidative
phosphorylation is linked to AD pathophysiological alterations
(Shoffner, 1997; Yao et al., 2009). Among the different levels of
glucose metabolism, oxidative phosphorylation occurring in
mitochondria may be thought as the process with a high risk of
being impaired due to the following reasons: Firstly, oxidative
phosphorylation is a multi-step metabolic process that com-
prises many enzyme complexes (from I to IV), coenzymes, as
well as metals and cytochromes (Shoffner, 1997). Dysfunction of
each element contributes to the disruption of oxidative
phosphorylation and subsequent glucose hypometabolism.
Secondly, oxidative phosphorylation is the ﬁnal step of cell
ATP production, any accidental breakdown of foregoing meta-
bolic processes, like glycolysis or TCA cycle may affect the
physiological function of oxidative phosphorylation. Finally,
oxidative phosphorylation occurs in mitochondria, which is a
susceptible organelle that tends to be inﬂuenced by different
kinds of harmful factors, like external apoptosis signal, calcium
overload and oxidative stress (Baloyannis, 2006; Bubber et al.,
2005; Gibson et al., 2000).
Thus, the defects of oxidative phosphorylation might present
among different aspects. Parker et al. (1994) found the activities of
cytochrome c oxidase (COX) is more severely affected in the
electron transport chain of AD brain. Further investigations of COX
kinetics in AD brain revealed abnormalities in substrate bindingkinetics (Parker and Parks, 1995). COX impairment is also found in
the cingulate cortex and other cortical brain regions of AD patients
(Hirai et al., 2001). However, some studies did not report
signiﬁcant COX defects. Cooper et al. (1993) reported normal
COX activity in AD temporal lobe mitochondria. By mitochondrial
DNA analyses, Reichmann et al. (1993) also demonstrated that no
speciﬁc defects of respiratory chain were discovered although
enzymes representing complex II, III and IV were reduced in
activities. However, the biopsies of frontal neocortex from AD
patients illustrated partial oxidative phosphorylation uncoupling
in respiration chain (Sims et al., 1987). This study raises the
hypothesis that Ab accumulation in AD brain may participate in
the deterioration of oxidative phosphorylation, as well as
mitochondrial oxidative stress.
4.2.2.2. Mitochondrial dysfunction and oxidative stress. The vicious
cycle initiated by AD speciﬁc pathophysiological alterations such
as Ab deposit, and comprised of AD speciﬁc pathophysiological
alterations, oxidative phosphorylation dysfunction and oxidative
stress could be the ﬁnal force to cause AD onset. With increasing
age as the primary risk factor for AD, mitochondrial respiratory
function in ageing brain manifests a gradual decline and is difﬁcult
to constantly meet high energy consumption. It leads to the
generation of redundant reactive oxygen species (ROS) and
oxidative damage. Because mitochondria are also the main
location suffering from ROS, oxidative stress further exacerbated
mitochondrial dysfunction and the vicious circle starts gradually in
ageing brain. Under genetic background and pathophysiological
condition of AD, oxidative stress and this vicious circle are more
prone to take place and have been demonstrated as an early event
occurring before the appearance of senile plaques and onset of
clinical manifestations (Bishop et al., 2010; Bonilla et al., 1999;
Chong et al., 2005; Clark et al., 2010; Engelhart et al., 2002).
Mitochondria are highly dynamic organelles that constantly
ﬁssure and fuse within the cell as the environment demands
(Chan, 2006). Mitochondrial dysfunction in AD has been demon-
strated the association with the imbalance of mitochondrial ﬁssion
and fusion (Bonda et al., 2010; Wang et al., 2008). In addition,
mitochondrial dysfunction in AD also includes enhanced mito-
chondrial permeability, reduced mitochondrial calcium modulat-
ing capacity and the release of pro-apoptogenic factors (Lloret
et al., 2008).
As the most recognized pathophysiological hallmark of AD, Ab
deposition is also involved in mitochondrial dysfunction in AD. The
deﬁnitive evidence has shown that Ab accumulation in mitochon-
dria of AD patients and mouse models occurs before extracellular
amyloid deposition and increases with age (Devi et al., 2006; Du
et al., 2008; Hirai et al., 2001; Manczak et al., 2006). Soluble Ab
oligomers harmfully impact on mitochondrial and neuronal
properties/function through disrupting functions of respiratory
chain (Cardoso et al., 2001) and other mitochondrial components
such as cyclophilin D (Du et al., 2008), Ab binding alcohol
dehydrogenase (Lustbader et al., 2004) and TOMM40 (Devi et al.,
2006). Besides, Ab has been demonstrated to contribute to the
defects of mitochondrial oxidative phosphorylation function.
There are three major APP isoforms that can be produced by
alternative splicing. By overexpressing one of these APP isoforms
APP-751 in primary cultures of human muscle using an adenovirus
vector, the study found APP-751 could cause decrease in COX
activity and ultrastructural abnormality of mitochondria (Askan-
sas et al., 1996). In rat hippocampal neurons, Ab has a destructive
effect on oxidative phosphorylation, which is related to the
inhibition of complex II activity (Kaneko et al., 1995). These studies
raise the hypothesis that Ab accumulation in AD brain may
participate in the deterioration of oxidative phosphorylation, as
well as mitochondrial oxidative stress.
Fig. 2. The diagram of multiple pathogenic cascades in Alzheimer’s disease. The
multiple pathogenic mechanisms contribute to the pathological hallmarks of
Alzheimer’s disease consisted of synapse and neuronal loss, amyloid plaques, and
neuroﬁbrillary tangles. Perturbed cerebral energy metabolism plays a central role in
multiple pathogenic cascades of Alzheimer’s disease.
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Hitherto, the amyloid cascade hypothesis is undoubtedly the
most convincing assumption for AD pathogenesis. The compelling
genetic evidence from human and animal models strongly
supports its objectivity. Recent study further strengthened the
supporting evidence for amyloid hypothesis, which a coding
mutation (A673T) in the APP gene delays cognitive decline and AD
onset in the elderly (Jonsson et al., 2012). Down syndrome, also
known as trisomy 21, manifests early-onset cognitive decline due
to brain amyloid deposits induced by the increase of APP gene copy
number (Webb and Murphy, 2012). APOE e4 allele is the most
recognized risk factor for sporadic AD and has been demonstrated
to damage the capacity of cellular Ab clearance (Swartz et al.,
1999). In addition, Amyloidogenesis-related animal models
through genetic manipulation further increase the persuasiveness
of the amyloid cascade hypothesis. All these clinical and
experimental studies provide a convincing pathophysiological
link between abnormal amyloid metabolism and neurodegenera-
tion.
However, there are still many sphinxes to be unveiled about the
amyloid cascade hypothesis. As one of the prominent pathophysi-
ological hallmarks of AD, brain amyloid deposit includes extracel-
lular amyloid plaques and intracellular soluble amyloid
enhancement. Extracellular amyloid plaques have been excessive-
ly emphasized but intracellular soluble amyloid received scant
attention in AD studies. Many clinical trials against AD targeting
extracellular amyloid plaques failed and acquired little beneﬁcial
effects on delaying or stopping neurodegeneration although
extracellular amyloid plaques were eliminated (Gravitz, 2011;
Holmes et al., 2008). This oppressive fact implies that extracellular
amyloid plaques only are vestiges of neural death induced by
intracellular excessive amyloid loading. This concept is also
supported by the observation of that amyloid plaques contain
many cytoskeletal components (Masters et al., 1985). Thus,
intracellular amyloid deposit may be a real culprit of neurode-
generation.
In addition, APP and its metabolites as well as related metabolic
enzymes such as b- and g-secretases play the key roles in many
physiological processes of neural cells (Bekris et al., 2011; De
Strooper et al., 2012; Zhang et al., 2011b). It makes AD treatment of
inhibiting Ab production in a dilemma: How to inhibit the
production of toxic Ab in the case of avoiding side effects? Current
studies have failed to provide methods that satisfy both sides.
Furthermore, previous evidence has shown that occurrence of
hypometabolism in AD brain did not parallel to the deposits of
amyloid accumulation (Berti et al., 2010), which may indicate that
glucose metabolism impairment and Ab accumulation are two
independent pathway that initiated AD pathology. Thus, the
amyloid hypothesis is not complete and sufﬁcient to interpret AD’s
phenotype, and needs to be complemented by the hypothesis of
glucose metabolism impairment.
Both clinical and experimental studies have conﬁrmed that
impaired cerebral glucose metabolism is an invariant pathophysi-
ological feature and precedes clinical symptoms and pathological
alterations even for decades (Cunnane et al., 2011; Jack et al., 2010;
Reiman et al., 1996; Small et al., 1995). Thus, we proposed a
hypothesis that impaired cerebral glucose metabolism, especially
altered thiamine metabolism and insulin resistance, could
promote Ab accumulation and tau hyperphosphorylation, as well
as induce multiple pathogenic factors, which synergistically make
for the pathological dysfunction of brain in AD. These pathophysi-
ological cascades include mitochondrial dysfunction and oxidative
stress (Gibson and Blass, 2007; Jhala and Hazell, 2011; Karuppa-
gounder et al., 2009), inﬂammatory factors (Calingasan andGibson, 2000; Karuppagounder et al., 2007; Watson and Craft,
2006), excitotoxicity (Hazell and Butterworth, 2009), AGEs (Vitek
et al., 1994; Yan et al., 1996), apoptosis (Moley and Mueckler,
2000), hyper-activation of some protein kinases (Salminen et al.,
2011; Zhao et al., 2011), and so forth (Fig. 2). All these pathogenic
factors are involved in cognitive dysfunction and the formation of
AD pathophysiological alterations.
From previous studies, impaired energy metabolism was shown
topromote Ab accumulation. Insulin resistance leads to excess
activation of GSK-3b, which may facilitate b-secretase activity and
Ab formation, resulting in increased intracellular Ab levels (Kim
and Feldman, 2012; Moreira et al., 2009). IDE participates in the
degradation of several extracellular substrates, like insulin and Ab.
Insulin has also been proposed to regulate extracellular degrada-
tion of Ab by modulating the IDE activity (Zhao et al., 2007). The
negative correlation between IDE activity and hippocampal Ab
content has been demonstrated in severe AD patients (Salminen
et al., 2011; Zhao et al., 2011). Moreover, energy production
impairment induces Ab accumulation. Reduced energy production
in transgenic mice increased cerebral BACE1 levels compared with
control (Velliquette et al., 2005). The authors also showed that TD
may increase BACE1 levels and Ab accumulation due to its induced
hypometabolism. Similarly, disruption of electron transportation
was also reported to cause the formation of amyloid fragments of
APP. Furthermore, normal wild-type mice with TD was shown to
promote the formation of neuritic clusters that could bind to
several antibodies for amyloid precursor protein (APP) and
amyloid precursor-like proteins, though plaques were not formed
(Calingasan et al., 1995). By using pyrithiamine, an anti-thiamine
compound, we have demonstrated that altered thiamine metabo-
lism increases b-amyloid accumulation, Tau hyperphosphoryla-
tion, and glycogen synthase kinase-3 activity in transgenic mice
brain (Zhao et al., 2011). However, to date, there is no report to
conﬁrm that TD can lead to Ab aggregation in humans. On the
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phosphorylation. Glucose transporters abnormality increase tau
hyperphosphorylation and NFTs formation (Liu et al., 2008).
Insulin resistance promotes tau hyperphosphoyrlation through
PI3K/Akt pathway (Correia et al., 2012). In the patients with
Wernicke–Korsakoff syndrome characterized by severe TD, tangles
have been found in their brains, especially in chronic alcoholics
(Cullen et al., 1997). In all, glucose metabolism impairment could
increase Ab aggregation and tau hyperphosphorylation via
different mechanisms. However, multiple pathogenic cascades
induced by impaired glucose metabolism could be the fundamen-
tal impetus to form AD phenotype. These multiple pathogenic
cascades include oxidative stress and mitochondria dysfunction,
AGEs production, inﬂammatory factors, excitotoxicity, autophagy
impairment, and GSK-3 activation and so on.
Although human brain only occupies 2% of the body by weight,
brain metabolism requires about 20% of the oxygen supplied by the
whole respiratory system (McKenna et al., 2006; Sokoloff, 1999).
Thus, it is an organ with high energy production and consumption,
which makes it more susceptible to mitochondria abnormality and
oxidative stress than any other organs. Current research, in fact,
suggests that both mitochondria dysfunction and oxidative stress
play an important role in the AD pathogenesis. Oxidative stress is a
result of misbalance of oxidative mechanism and antioxidant
mechanism of the cells. Some investigators proposed a two-hit
hypothesis to explain the role of oxidative stress in AD pathology
(Wang et al., 2009a). Moreover, oxidative markers, generally like 8-
hydroxyguanosine (8-OHG) appears to precede all the typical
hallmarks of AD, such as NFTs and Ab plaques. Speciﬁcally, studies
showed that 8-OHG appears decades prior to Ab aggregation. The
Tg2576 transgenic mice exhibited oxidative damage prior to Ab
aggregation (Melov, 2004; Stowers et al., 2002; Wang et al., 2008).
In AD, iron deposition has been demonstrated to show the
association with oxidative stress, which causes increased protein
and DNA oxidation, and inactivation of the human brain
muscarinic cholinergic receptor required for memory (Jomova
et al., 2010; Salvador et al., 2010; Fawcett et al., 2002). Moreover,
iron chelators, such as intranasal desferrioxamine, also have been
demonstrated to show beneﬁcial effects in AD patients or AD
transgenic models. Thus, iron deposition may play a signiﬁcant role
in the pathogenesis of AD (Crapper McLachlan et al., 1991; Hanson
et al., 2012; Fine et al., 2012). In this case, oxidative stress is
supposed to be an original contributor to AD pathogenesis.
Glucose-6-phosphate dehydrogenase (G6PDH) is the rate-limiting
enzyme of the phosphate pentose shunt (PPP) (McKenna et al.,
2006; Sokoloff, 1999), which plays an essential role in the redox
balance of cells. It participated in homeostatic redox control by
providing reducing equivalents to glutathione. Russell et al. (1999)
have found an up-regulation of G6PDH together with increased
sulfhydryls in AD, which suggests that reductive compensation
plays a crucial role in ﬁghting oxidative stress in AD. Thus, by
removing the ROS produced by neuronal oxidative stress, neurons
may provide themselves a useful approach for self-protection in
AD brain. Carbonyl stress marked by AGEs could also induce cell
dysfunction, which contributes to AD pathology (Russell et al.,
1999; Vitek et al., 1994). AGEs have been demonstrated to be a
common pathological pathway resulting in CNS disease progres-
sion. Compared with young people and non-demented controls,
AGEs have been found to increase in neurons of aging and AD, and
even worse with the progression of AD (Martina and Gerald, 2010).
Interestingly, intracellular AGEs accumulation has been observed
in 75–95% of pyramidal neurons of patients with familial AD (PS1
mutations) (Munch et al., 2002), which indicates that AGEs may
contribute to increased neuronal dysfunction and vulnerability.
Impaired glucose metabolism induces mitochondria dysfunc-
tion and oxidative stress, which may lead to the activation ofapoptotic pathway mediated by mitochondria. Apoptosis, or
programmed cell death, plays important roles in brain develop-
ment, as well as neurodegenerative disease, including AD.
Mitochondria have been characterized as a location where
apoptosis can be induced by AD-related pathogeneses, such as
oxidative stress, disruption of oxidative phosphorylation, mtDNA
mutations and so on (Cottrell et al., 2002). The previous researches
also reported that apoptosis participated in the neuron loss of AD,
and mitochondria are the main organelles that mediate these
apoptotic effects. Firstly, neurons with AD speciﬁc mutation (like
PS1 mutant) have been demonstrated to exhibit increased
sensitivity to mitochondria toxin-induced apoptosis (Chan et al.,
2002), which is mediated by calcium overload and excess oxidative
stress. Moreover, it has also been demonstrated that Ab1-42 could
promote the release of cytochromose c from mitochondria of AD
neurons, and initiate the process of neuronal apoptosis (Zhang
et al., 2002), which can be inverted by antioxidate glutathione
suggesting the involvement of oxidative stress in mitochondria
dysfunction. Thus, blocking the mitochondria apoptosis signaling
or related cascades could be a potential approach to prevent
apoptosis and neuron loss in AD.
Though impaired glucose hypometabolism could induce
inﬂammatory responses in AD brain and exacerbate AD’s
pathology, the inﬂammatory factors are generally regarded as
products of other critical insults, such as Ab, oxidative stress, and
mitochondrial dysfunction. Former evidence has demonstrated
that inﬂammatory factors participate in the pathogenesis of AD. IL-
1, IL-6, TGF-b all have been found in AD brains by autopsy, and may
play a destructive role in AD progression (Neuroinﬂammation
Working Group, 2000; Lukiw and Bazan, 2010; Sardi et al., 2011).
In addition, microglia and astrocytes have also been shown to be
involved in the inﬂammation in AD. Microglia clusters located in
Ab deposits have be found in both the brains of AD patients and
APP transgenic mice (McGeer et al., 1989). It has also been shown
that cultured microglia can secrete Ab and metabolize APP in a
manner promoting Ab deposition (Barnum et al., 1996). Moreover,
microglia have also been demonstrated to aggregate much more
around Ab-containing neuritic plaques than fuse plaques in AD, in
normal aging, as well as in APP transgenic mice. Furthermore,
many different laboratories have shown that microglia, both in vivo
and in vitro, phagocytose exogenous ﬁbrillar Ab (Frautschy et al.,
1992, 1998; Oliver et al., 1997; Paresce et al., 1997). Finally,
pathophysiologic relevance of inﬂammation to AD neurodegen-
eration has been established by multiple lines of converging
tangential and direct evidence (in review Neuroinﬂammation
Working Group, 2000).
Normal glucose metabolism is necessary to any cellular process,
including autophagy, which responds to alterations of cell energy
metabolism. Autophagy is a critical pathway involved in the
elimination of proteins and organelles, and is highly conserved
during evolution (Mizushima et al., 2008; Tung et al., 2012). The
physiological function of autophagy is to help cells survive in
nutrient starvation and stress. Loss of autophagy could result in
CNS neurodegeneration (Komatsu et al., 2006). Suppression of
basal autophagy in neural cells could lead to neurodegenerative
disease in mice (Hara et al., 2006). It has been found that an
important autophagy process initiating regulator, Beclin 1, is
decreased in AD patients (Pickford et al., 2008). Knockout mice
lacking Beclin-1 (Bcn1/) die during embryogenesis (Qu et al.,
2003; Yue et al., 2003). In contrast, Bcn1+/ mice are viable. They
have reduced autophagosome formation in skeletal muscle,
bronchial epithelial cells and B lymphocytes (Qu et al., 2003),
but the neuronal phenotype of these mice has not been
characterized. Macroautophagic markers are proved to be related
to senile plaques and tangles, including Atg5, Atg12, and LC3 in
AD (Ma et al., 2010). Moreover, it has been demonstrated that
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peptides in an APP-overexpressing cell line as well as in AD mouse
models (Lunemann et al., 2007; Yu et al., 2004), which may
indicate that autophagy participate in the process of Ab
degradation. Actually, by deletion of Beclin 1, cells exhibit
increased Ab peptides, full-length APP, as well as APP C-terminal
fragments (APP-CTFs) (Jaeger et al., 2010). Consistent with this, in
mouse model with Beclin 1 down-regulation also showed serious
neurodegeneration marked by intracellular and extracellular Ab
accumulation (Lunemann et al., 2007; Yu et al., 2004). In contrast,
gene therapy using locally injected lentivirus loading Beclin-1
reduced Ab aggregates in APP transgenic mice (Pickford et al.,
2008). Based on these results, autophagy is important in the
degradation of Ab deposits, and could play a critical role in the
pathogenesis of AD.
The mammalian target of rapamycin (mTOR) pathway plays a
major role in receiving autophagic stimuli with its ability to sense
nutrient and metabolic hormonal signals to initiate autophagy (Cai
et al., 2012). The mTOR-dependent signaling pathway seems to be
involved in AD patients’ brains as well as in AD models (Li et al.,
2005; Pei and Hugon, 2008). Enhanced mTOR signaling activity
increases Ab deposits and NFTs formation in AD (Lafay-Chebassier
et al., 2005). Inhibition of mTOR by rapamycin retards cognitive
deﬁcits and reduces Ab pathology by increasing autophagy in AD
models (Bove et al., 2011). Autophagy impairment also increases
b- and g-secretases activities, which results in Ab overproduction
and accumulation (Cai et al., 2012). In addition, autophagy
impairment contributes to the tauopathy (Hamano et al., 2008;
Murakami et al., 1998; Schaeffer et al., 2012; Wang et al., 2009b).
Apart from the roles in Ab production and tauopathy, autophagy
impairment has been demonstrated to disrupt cell’s physiological
function by mitochondria dysfunction and oxidative stress, and it
also exacerbates insulin resistance via reductions of insulin
secretion in pancreas b cells (Wang et al., 2013). To sum up,
autophagy is essentially responsible for the degradation of folded
proteins in cells, and its dysfunction could lead to Ab aggregation
and tauopathy.
It has been reported that excitotoxicity is an early event in the
onset of AD, which was demonstrated by neuropathological and
neurochemical studies in AD brain (Cai et al., 2012; Hynd et al.,
2004). Impaired glucose metabolism is an important contributor to
excitotoxicity via disruption of astrocytes’ normal uptake mecha-
nism of glutamate. Clinical trials for AD therapy using N-methyl-D-
aspartic acid receptor (NMDAR) antagonist memantine have been
showed to improve AD patients’ cognitive functions and display
good tolerance (Frankiewicz and Parsons, 1999). Thus, excitotoxi-
city may play a critical role in AD pathogenesis. Some mechanisms
have been proposed to explain NMDAR’s excitotoxicity in AD
pathology. They have showed that NMDAR is a receptor for Ab
oligomers and the interaction of NMDAR and Ab could be
neurotoxic (Tominaga-Yoshino et al., 2001). Furthermore, in
post-mortem AD brains, co-localization of Ab plaques, NFTs and
excitatory pyramidal neurons also support the above-mentioned
results (Braak et al., 1993). Thus, exictotoxicity could be a
pathological mechanism involved in AD.
Glucose metabolism dysfunction could be inﬂuenced by GSK-3
activity, thus GSK-3 may be one of the mediators that participate in
the AD pathophysiological process. For example, GSK-3 activation
signiﬁcantly increases production of Ab and hyperphosphorylated
tau through a dual pathway mechanism. Cumulative evidence has
proved that GSK-3 increases tau phosphorylation, Ab aggregation,
memory impairment, as well as microglia activation-associated
inﬂammatory reactions in AD (Hooper et al., 2008). An investiga-
tion showed that GSK-3 reduces acetylcholine synthesis, and acts
as a mediator of apoptosis (Hoshi et al., 1996). AD brain tissues
have been found to exhibit increase of expression or activity ofGSK-3 (Blalock et al., 2004), and hence hyper-activation of GSK-3
could induce the apoptosis of cholinergic neurons (Hoshi et al.,
1996), tau-hyperphosphoryaltion (Cho and Johnson, 2003; Love-
stone et al., 1994), and subsequent NFTs formation (Lucas et al.,
2001). Furthermore, the studies have demonstrated that GSK-3a
has been demonstrated to modulate APP cleavage and induce Ab
production (Phiel et al., 2003; Sun et al., 2002), and that blockade of
GSK-3b could prevent Ab accumulation (Alvarez et al., 1999;
Takashima et al., 1993). GSK-3 is also involved in the induction of
long term potentiation (LTP) (Hooper et al., 2007), and over-
expression of GSK-3 could prevent the induction of LTP by
negatively regulating Wnt or PI3K signaling (Hooper et al., 2007).
Thus, the preventive effects of GSK-3 on LTP could lead to memory
impairment in vivo and hence plays a role in AD cognitive deﬁcits.
In conclusion, AD is a complicated disease involved in multiple
pathophysiological cascades induced by perturbed glucose me-
tabolism. Combined with Ab accumulation and NFTs formation,
impaired glucose metabolism and its downstream pathophysio-
logical alterations form a vicious cycle, which synergistically make
for the pathological dysfunction of brain in AD. In this vicious cycle,
impaired cerebral glucose metabolism plays a central role that can
easily be modiﬁed. It is due to that correcting impaired cerebral
glucose metabolism does not result in the dilemma situation like
the treatment of reducing Ab production. Secondly, brain glucose
hypometabolism can independently cause AD pathological hall-
marks, including Ab plaques, tau hyperphosphorylation, synaptic
and neuronal loss as well as other pathophysiological cascades in
AD brain, which all contribute to AD pathogenesis (Fig. 2).
6. Implications for diagnostic and intervention strategies of
Alzheimer’s disease
The above-mentioned hypothesis provides a glimmer of
sunlight for the current predicament of AD study. Indeed, it is
time to change our strategies for AD diagnostic and intervention
studies if we hope the long list of failed AD clinical trials no longer
last in the future (Castellani and Perry, 2012).
6.1. New strategy for Alzheimer’s disease diagnosis
The present clinical diagnosis of AD still relies primarily on
clinical symptoms and neuropsychological tests. The existing AD
biomarker tests can be divided into three categories: (1) CSF Ab
detection and cerebral PiB-PET examination reﬂecting abnormal
amyloid metabolism in AD brains (Palmert et al., 1990; Price et al.,
2005; Rosenmann, 2012), (2) CSF tau detection and structural MR
imaging reﬂecting neurodegeneration (Rosenmann, 2012; Vigo-
Pelfrey et al., 1995), and (3) FDG-PET reﬂecting the functional
status of cerebral glucose metabolism (McKhann et al., 2011; The
Ronald and Nancy Reagan Research Institute of the Alzheimer’s
Association and the National Institute on Aging Working Group,
1998). Although these existing biomarker tests can increase the
certainty of AD diagnosis, they have not been recommended for
routine diagnostic purposes in new AD diagnosis guideline due to
several shortcomings as compared with ideal biomarker tests
(McKhann et al., 2011). Ideal biomarker tests for AD diagnosis
should not only reﬂect the fundamental pathophysiological
features but also be reliable, non-invasive, simple-to-perform
and inexpensive (Noel-Storr et al., 2012). However, the existing
biomarker tests are either expensive (PiB-PET or FDG-PET) or
invasive (CSF b-amyloid and tau), and all are difﬁcult to perform.
These shortcomings severely limit the application of the existing
biomarker tests in clinical practice of AD diagnosis. In addition, AD
dementia stage has been irreversible. It is too late to modify the
disease when we diagnose patients as AD in this late stage. The
existing biomarker tests are not suitable for screening the high risk
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ideal biomarker tests for AD diagnosis is still needed.
Brain glucose hypometabolism is an invariant biomarker, which
precedes clinical manifestations of AD for years or even decades
(Mosconi et al., 2008a, 2006). The pathophysiological alterations
associated with cerebral glucose mal-metabolism may serve as
ideal biomarkers for AD diagnosis. Among these alterations,
altered thiamine metabolism is the most promising candidate.
Both clinical and experimental studies have demonstrated that
thiamine-dependent biological processes and thiamine metabo-
lism are speciﬁcally involved in AD (Gold et al., 1998; Gold, 2005;
Zhang et al., 2011a).
As the possible pathogenic factor of impaired glucose metabo-
lism, altered thiamine metabolism should precede the alterations
of brain glucose metabolism and subsequent cognitive deﬁcits.
Thus, altered thiamine metabolism is an early biomarker for AD
diagnosis. Further clariﬁcation of abnormal thiamine-dependent
processes as well as the cause and pathogenesis of altered thiamine
metabolism may provide more biomarkers for AD diagnosis and
prediction.
6.2. New strategies for the prevention and treatment of Alzheimer’s
disease
Though AD has been studied for more than 100 years (Berchtold
and Cotman, 1998), there is no effective disease-modifying
treatments. Since last century, the researchers have tried to
develop reliable and effective therapeutics for AD treatment based
on the amyloid hypothesis (Asai et al., 2006; Comery et al., 2005;
Schenk et al., 1999) and tau hyperphosphorylation hypothesis
(Noble et al., 2005). However, most of clinical trials targeting at Ab
are not demonstrated to show more signiﬁcance efﬁcacy than
control placebo, though some of them effectively clear Ab deposits
in AD brain (Gravitz, 2011; Holmes et al., 2008; Gilman et al., 2005;
Orgogozo et al., 2003). The researchers also dedicated to ﬁnd
effective antioxidants (Zandi et al., 2004), anti-inﬂammation
(Aisen et al., 2006), and neuroprotective approaches (Tuszynski
et al., 2005) for AD therapy. Unfortunately, the antioxidants (Zandi
et al., 2004), anti-inﬂammatory agents (Aisen et al., 2000; Scharf
et al., 1999) were also shown to be ineffective. Currently, there are
ﬁve medications that are approved for treating AD in North
America and most countries in Europe: memantine (an NMDAR
antagonist) and four cholinesterase inhibitors: tacrine, donepezil,
galantamine, and rivastigmine (Herrmann et al., 2011). However,
all of them are only symptomatic therapies and can not halt and
reverse AD pathology. Hence, developing effective disease-
modifying therapies is the focus of future study for AD prevention
and treatment.
AD is an insidious and progressive neurodegenerative disease.
When the patients with overt symptoms of cognitive dysfunction
are diagnosed as AD, the disease has gone through for many years
or even for decades. Theoretically, AD includes four stages: Pre-
disease stage (no detectable pathophysiological alterations), pre-
clinical stage (with detectable pathophysiological alteration(s) but
without cognitive impairments), pre-dementia stage (MCI stage),
and dementia stage. Different strategies of AD prevention and
treatment should be chosen for the different disease stages. To
develop different preventive or therapeutic ‘‘formula’’ for each
disease stage could be a priority for our future AD study. At the pre-
disease and pre-clinical stages of AD, we should prevent the onset
of the disease by controlling the initial pathogenic factor(s) of the
disease, such as insulin resistance. At the pre-dementia stage, we
could stop the disease progression by applying different combina-
tions of preventive and curative drugs. At the dementia stage, we
should develop ‘‘cocktail therapies’’ or drugs targeting multiple
pathogenic mechanisms of AD. Hence, we proposed a new modelfor future AD therapy research based on our perspectives of AD
pathophysiology (Fig. 3). In this model, we proposed a perspective
of ‘‘personal therapy for AD’’ based on the different disease stages
and correspondent biomarkers and pathogenic cascades. Different
disease stages are labeled by different biomarkers and pathogenic
cascades as disease progress, some of which have been proposed
by Jack et al. (2013).
Thus, the failure of current clinical trials of drugs with only a
single mechanism against AD at the dementia stage is not
surprising. In our opinion, the following two approaches should
be worth exploring to modify or halt the disease progress of AD:
Firstly, to develop effective therapeutics against glucose metabo-
lism dysfunction for AD prevention and early treatment. Secondly,
to develop ‘‘cocktail therapies’’ or drugs targeting at multiple
pathogenic cascades.
6.3. Drugs targeting altered thiamine metabolism and insulin
resistance
The previous studies have showed that TD is a usual
phenomenon in AD patients (O’Keeffe, 2000). Thus, the modiﬁca-
tion of altered thiamine metabolism could provide effective
therapeutic approach to AD. However, the studies have exhibited
the contradictory results of thiamine therapy in AD patients. A
study in 11 AD patients by Blass and his colleagues reported
signiﬁcant improvement of cognitive function with thiamine
therapy at 3 g/day orally in a 3-month crossover-design (Blass
et al., 1988), whereas a follow-up study by the same group found
no signiﬁcant effects in a 12-month parallel group design in 10 AD
patients (Nolan et al., 1991). Another study with thiamine therapy
at 3–8 g/day orally for 12 months suggested that thiamine may
have mild beneﬁcial effects in AD at higher dosages (Meador et al.,
1993). Combination of sulbutiamine and acetylcholinesterase
inhibitors has been demonstrated to have a persistent improve-
ment in early stage AD patients (Ollat et al., 2007). Fursultiamine
(TTFD), a derivative of thiamine, has been shown to have a mild
beneﬁcial effect in AD patients, but only mildly impaired subjects
showed cognitive improvement (Mimori et al., 1996). In our study,
we have shown that benfotiamine, but not fursultiamine was
beneﬁcial for improving cognitive dysfunction and cerebral
pathological alterations in APP/PS1 transgenic mice (Pan et al.,
2010). Benfotiamine effectively reduced amyloid plaque numbers
and phosphorylated tau levels in cortical regions of transgenic
mice, and also enhanced spatial memory of transgenic mice in
Morris water maze test, and this was demonstrated to be
associated with elevated GSK-3 phosphorylation. Although these
studies suggest that thiamine-related chemicals are potential
candidates with low cost and toxicity for AD treatment, the
extended double-blind, parallel-group design studies should be
performed to completely settle this issue. In addition, the ultimate
treatment always awaits a better understanding of the underlying
mechanisms. Thus, it is important to further clarify the exact cause
and mechanism of altered thiamine metabolism in AD.
Considering the common pathogeneses between T2DM and
AD such as insulin resistance, it is possible that therapeutics for
T2DM would be effective for AD (Zhong and Weisgraber, 2009).
Thus, correcting insulin resistance and repairing insulin signal-
ing dysfunction would be potential targets for AD therapy. One
of the most popular targets is PPARs, which belongs to steroid
hormone super family ligand-inducible transcription factors. It
can enhance insulin sensitivity, improve mitochondrial function,
modulate glucose metabolism, and reduce inﬂammatory
responses (de la Monte, 2012). Rosiglitazone is a g-PPAR agonist,
which has been widely used in T2DM treatment. In a small-scale
clinical trial, rosiglitazone was showed to preserve performance
on delayed recall and attention tasks compared with placebo
Fig. 3. The ‘‘personal therapy for AD’’ model. In this model, different clinical stages are labeled by different biomarkers and pathogenic cascades, some of which have been
proposed by Jack et al. (2013). The lower column ‘‘Biomarkers/pathophysiology’’ lists the biomarker proﬁles and pathogenic alterations for every stage of AD.
Correspondently, the upper column ‘‘Therapeutic ‘formulas’’’ assumes some potential interventions for AD prevention and treatment based on our perspective of AD
pathophysiology. We suggest that future AD treatment should focus on the prevention by early prediction and diagnosis in pre-disease stage and pre-clinical stage, and
treatment by targeting multiple pathogenic cascades in pre-dementia stage and dementia stage.
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to be effective only in APOE-4-negative subjects but not in APOE-
4-positive subjects (Risner et al., 2006). However, recent phase
three clinical trial has shown the negative effect of rosiglitazone
on objective cognitive performance in AD patients (Gold et al.,
2010). Another alternative therapy to correct insulin signaling
for AD is intranasal administration of insulin. Intranasal insulin
has been demonstrated to show improved memory in normal
adults without obvious side effects (Benedict et al., 2008; Krug
et al., 2010). Besides, intranasal insulin has shown to prevent
cognitive decline, cerebral atrophy, Ab accumulation and white
matter lesions in T1DM encephalopathy model (Francis et al.,
2008; Subramanian and John, 2012). In a rat model of T2DM,
intranasal insulin has also been found to reduce tau hyperpho-
sphorylation (Yang et al., 2013). Four phase two clinical trials of
intranasal insulin for early AD or MCI have shown to improve
memory and attention abilities without signiﬁcant adverse
effects as well as changes in blood levels of insulin or glucose
(Benedict et al., 2008; Craft et al., 2012; Dhamoon et al., 2009;
Djupesland, 2008; Reger et al., 2006, 2008a,b; Schioth et al.,
2012; Shemesh et al., 2012). One of advantages of this
therapeutic is non-invasive intranasal delivery method (Hanson
and Frey, 2008). Many studies have shown that intranasal
approach can directly deliver the drugs to brain (Dhuria et al.,
2010; Hanson and Frey, 2008). It is not surprising that intranasal
insulin treatment is a useful method for brain disorders,
including AD. Further phase three or four clinical trials could
be performed to testify its efﬁcacy and safety. Glucagon-like
peptide-1 (GLP-1), a member of the incretin family and which
originates from preproglucagon and secreted by intestinal
endocrine epithelial L-cells, may be a candidate drug for AD
treatment (Mossello et al., 2011). It is the strongest stimulator
for oral glucose-induced insulin secretion and exhibits the
improvement in insulin resistance and cognitive deﬁcits.
Considering the linkage between AD and T2DM in insulinresistance, GLP-1 or its analogues could be effective for AD
through intranasal delivery technology. Studies have showed
that extendin-4, a GLP-1 analogue, prevents the neurotoxicity of
cerebral Ab1-40 both in triple transgenic AD-mouse and STZ-
induced T2DM mouse (Bertilsson et al., 2008; Hamilton et al.,
2011). Another GLP-1 analogue, Val (8)-GLP-1(7-36), has been
shown to invert cognitive impairment and long term potentia-
tion (LTP) suppression induced by Ab1-40 (Wang et al., 2010).
Consistent with this, other studies also showed the beneﬁcial
effect of Val (8)-GLP-1 on LTP in APP/PS1 mice (Gengler et al.,
2012). Furthermore, the study also has shown that intranasal
GLP-1 administration using the novel device improves the
glycemic control in T2DM patients without any adverse effects
(Nakazato, 2011). Thus, GLP-1 and GLP-1 analogues through
intranasal administration could be potential therapeutics for AD.
Further trials should be performed in the future.
6.3.1. ‘‘Cocktail therapies’’ or drugs targeting at multiple pathogenic
cascades.
Based on our hypothesis of multiple pathogenic cascades
induced by glucose metabolism dysfunction in AD (Fig. 2), it may
be unavoidable to develop ‘‘cocktail therapies’’ or drugs targeting
multiple pathogenic cascades for AD treatment, similar to cancer
and AIDs therapies (Radhakrishnan and Tidor, 2008). Previous
basic experiments and clinical trials actually have provided some
examples for AD combination therapy (Masashi et al., 2010;
Sobow, 2010). The combination of memantine and cholinesterase
inhibitors (CHEIs) has been tried for AD treatment in the last
decade, some of them showed additive or synergistic effects (Beier,
2004; Fox et al., 2006; Moreira et al., 2006). The short-term efﬁcacy
of complement of memantine to ChEIs treatment has been
evaluated in some randomized controlled trials (Beier, 2004;
Porsteinsson et al., 2008), one of them showed signiﬁcant beneﬁts
of adding memantine verse placebo; but another trial failed.
Masashi et al. (2010) reported additive effects on the reduction of
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and g-secretase inhibitors. Other combinations have also been
tried, like tacrine–melatonin (Spuch et al., 2010), selegiline and
vitamin E (Sano et al., 1997), indomethacin and CHEIs (de Jong
et al., 2008). In addition, the supplement of compound nutrients
from natural dietary supplements may have some potential value
for AD treatment. Parachikova et al. (2010) have demonstrated that
medical food cocktail could improve cognitive function in AD
models.
In our ‘‘personal therapy for AD’’ model, different therapeutic
‘‘formulas’’ are listed in Fig. 3. We propose that future AD
treatment should focus on the prevention by early prediction and
diagnosis in pre-disease stage and pre-clinical stage, and treatment
by targeting at multiple pathogenic cascades in pre-dementia
stage and dementia stage. Additionally, the interaction and
compatibility of different drugs with different mechanism and
pharmacological effects should be carefully considered before the
combination therapies are applied. Combination of memantine
and CHEIs has shown some side effects and low efﬁcacy because of
incompatibility and cumulative toxicity (Porsteinsson et al., 2008).
In all, our perspectives highlight that the early intervention of
the disease and combinational therapies targeting multiple
pathogenic cascades in different disease stages are the core of
future AD research.
7. Conclusions
Though AD has been studied for over 100 years, there are still
some key problems to be addressed in its diagnosis, prevention,
and treatment. Recent researches have highlighted the role of
impaired brain glucose metabolism in AD pathophysiological
cascades. In this review, we proposed that AD is a complicated
disease due to multiple pathogenic mechanisms caused by
impaired cerebral glucose metabolism. Based on this hypothesis,
we discussed the alternative strategies for AD diagnosis and
intervention in the future. With the advances of AD studies, we
believe that the further understanding for AD pathogenesis will
help us to develop efﬁcient diagnostic approaches and treatment
methods.
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